🚀 VC round data is live in beta, check it out!
Wuxi Biologics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Wuxi Biologics and similar public comparables like Divi's Laboratories, Sartorius, Medpace, Eurofins Scientific and more.
Wuxi Biologics Overview
About Wuxi Biologics
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.
Founded
2014
HQ
Employees
12.6K
Website
Financials (LTM)
EV
$17B
Wuxi Biologics Financials
Wuxi Biologics reported last 12-month revenue of $3B and EBITDA of $1B.
In the same LTM period, Wuxi Biologics generated $2B in gross profit, $1B in EBITDA, and $743M in net income.
Revenue (LTM)
Wuxi Biologics P&L
In the most recent fiscal year, Wuxi Biologics reported revenue of $3B and EBITDA of $943M.
Wuxi Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $943M | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $743M | XXX | $492M | XXX | XXX | XXX |
| Net Margin | 22% | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Wuxi Biologics Stock Performance
Wuxi Biologics has current market cap of $19B, and enterprise value of $17B.
Market Cap Evolution
Wuxi Biologics' stock price is $4.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17B | $19B | 0.0% | XXX | XXX | XXX | $0.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialWuxi Biologics Valuation Multiples
Wuxi Biologics trades at 5.1x EV/Revenue multiple, and 13.1x EV/EBITDA.
EV / Revenue (LTM)
Wuxi Biologics Financial Valuation Multiples
As of April 19, 2026, Wuxi Biologics has market cap of $19B and EV of $17B.
Equity research analysts estimate Wuxi Biologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Wuxi Biologics has a P/E ratio of 25.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19B | XXX | $19B | XXX | XXX | XXX |
| EV (current) | $17B | XXX | $17B | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | 13.1x | XXX | 18.1x | XXX | XXX | XXX |
| EV/EBIT | 15.8x | XXX | 23.3x | XXX | XXX | XXX |
| EV/Gross Profit | 11.2x | XXX | 15.2x | XXX | XXX | XXX |
| P/E | 25.4x | XXX | 38.4x | XXX | XXX | XXX |
| EV/FCF | 43.3x | XXX | 90.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Wuxi Biologics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Wuxi Biologics Margins & Growth Rates
Wuxi Biologics' revenue in the last 12 month grew by 17%.
Wuxi Biologics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
Wuxi Biologics' rule of 40 is 55% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Wuxi Biologics' rule of X is 81% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Wuxi Biologics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 32% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 81% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Wuxi Biologics Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Wuxi Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Divi's Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Sartorius | XXX | XXX | XXX | XXX | XXX | XXX |
| Medpace | XXX | XXX | XXX | XXX | XXX | XXX |
| Eurofins Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| Wuxi XDC | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wuxi Biologics M&A Activity
Wuxi Biologics acquired XXX companies to date.
Last acquisition by Wuxi Biologics was on XXXXXXXX, XXXXX. Wuxi Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Wuxi Biologics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialWuxi Biologics Investment Activity
Wuxi Biologics invested in XXX companies to date.
Wuxi Biologics made its latest investment on XXXXXXXX, XXXXX. Wuxi Biologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Wuxi Biologics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Wuxi Biologics
| When was Wuxi Biologics founded? | Wuxi Biologics was founded in 2014. |
| Where is Wuxi Biologics headquartered? | Wuxi Biologics is headquartered in China. |
| How many employees does Wuxi Biologics have? | As of today, Wuxi Biologics has over 12K employees. |
| Who is the CEO of Wuxi Biologics? | Wuxi Biologics' CEO is Zhisheng Chen. |
| Is Wuxi Biologics publicly listed? | Yes, Wuxi Biologics is a public company listed on HKEX. |
| What is the stock symbol of Wuxi Biologics? | Wuxi Biologics trades under 02269 ticker. |
| When did Wuxi Biologics go public? | Wuxi Biologics went public in 2017. |
| Who are competitors of Wuxi Biologics? | Wuxi Biologics main competitors are Divi's Laboratories, Sartorius, Medpace, Eurofins Scientific. |
| What is the current market cap of Wuxi Biologics? | Wuxi Biologics' current market cap is $19B. |
| What is the current revenue of Wuxi Biologics? | Wuxi Biologics' last 12 months revenue is $3B. |
| What is the current revenue growth of Wuxi Biologics? | Wuxi Biologics revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Wuxi Biologics? | Current revenue multiple of Wuxi Biologics is 5.1x. |
| Is Wuxi Biologics profitable? | Yes, Wuxi Biologics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Wuxi Biologics? | Wuxi Biologics' last 12 months EBITDA is $1B. |
| What is Wuxi Biologics' EBITDA margin? | Wuxi Biologics' last 12 months EBITDA margin is 39%. |
| What is the current EV/EBITDA multiple of Wuxi Biologics? | Current EBITDA multiple of Wuxi Biologics is 13.1x. |
| What is the current FCF of Wuxi Biologics? | Wuxi Biologics' last 12 months FCF is $393M. |
| What is Wuxi Biologics' FCF margin? | Wuxi Biologics' last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Wuxi Biologics? | Current FCF multiple of Wuxi Biologics is 43.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.